Increase in plasma Malondialdehyde-modified low-density lipoprotein in patients with atherothrombotic cerebral infarction

Tokai Journal of Experimental and Clinical Medicine

Volumn 30, Issue 3, 2005, Pages 171-176

  Kametsu, Yutaka ^a   Kitagawa, Yasuhisa ^b   Sekiyama, Sari ^c   Takagi, Shigeharu ^c  

^a TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

^b TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cerebral infarction; IMT; MDA LDL; Oxidized LDL; Statin

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PRAVASTATIN;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; B SCAN; BRAIN INFARCTION; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DOPPLER FLOWMETRY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; PROTEIN DEGRADATION; PROTEIN MODIFICATION; QUALITATIVE ANALYSIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TUNICA MEDIA;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CAROTID ARTERIES; CEREBRAL INFARCTION; CHOLESTEROL, LDL; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; PRAVASTATIN; STATISTICS; ULTRASONOGRAPHY, DOPPLER;

EID: 28244478985     PISSN: 03850005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bujoh H, Kotani K, Saitoh K et al. MDA-LDL blood levels and progression of carotid hypertrophy during therapy with statins. J. Japan Atherosclerosis Society 29 suppl: 268, 2001.
2. Ehara S, Ueda M, Naruto T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103: 1955-1960, 2001.
3. Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 21: 844-848, 2001.
4. Holvoet P, Perez G, Zhao Z et al. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 95: 2611-2619, 1995.
5. Holvoet P, Vanhaecke J, Janssens S et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98: 1487-1494, 1998.
6. Jessup W, Kritharides L. Metabolism of oxidized LDL by macrophages. Curr Opin Lipidol 11: 473-481, 2000.
7. Joint committee with the Guidelines Subcommittee of the Japan Academy of Neurosonology for Ultrasonic Assessment of Carotid Artery Disease and the Subcommittee for Research into Methods of Screening Atherosclerotic Lesions. Guidelines for ultrasonic assessment of carotid artery disease: Preliminary report. Neurosonology 15: 20-33, 2002.
8. Kotani K, Kondo A, Manabe M, et al. Determination of malondialdehyde- modified LDL (MDA-LDL) and its potential usefulness. Jpn J Clin Pathol 45: 47-54, 1997.
9. Kotani K, Maekawa M, Kanno T, et al. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta 1215: 121-125, 1994.
10. Miyazaki T, Shimada K, Sato O, et al. Circulating malondialdehyde- modified LDL and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery disease. Atherosclerosis 179: 139-145, 2005.
11. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 138: S419-20, 1999.
12. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modification of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915-24, 1989.
13. Steinberg D. Role of oxidized LDL and antioxidants in atherosclerosis. Adv Exp Med Biol 369: 39-48, 1995.
14. Tamura A, Watanabe T, Nasu M. Effects of atorvaststin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients. Circulation Journal 10: 816-820, 2003.
15. Tanaga K, Bujo H, Inoue M, et al. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery disease and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol 22: 662-6, 2002.
16. Toshima S, Hasegawa A, Kurabayashi M, et al. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 20: 2243-2247, 2000.
17. Witztum JL. Immunological response to oxidized LDL. Atherosclerosis 131(suppl): S9-S11, 1997.
18. Ylä-Herttuala S, Palinski W, Rothenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84: 1086-1095, 1989.